CBD and Clobazam: Unprecedented Exaggeration

Some recent highlights and curiosities from the amazing world of cannabis science and therapeutics.
By Adrian Devitt-Lee On November 04, 2019
An illustration of two doctors, on female-presenting and one male presenting. She carries an giant prescription pill bottle while he gives a thumbs up and carries a clipboard.

A recent publication in Epilepsia described some aspects of the interaction between cannabidiol and clobazam, an antiepileptic drug, using preclinical models. The researchers claim “we provide unprecedented evidence that CBD potently inhibits the metabolism of clobazam… and, to a lesser extent [its metabolite, N-desmethylclobazam].” While their study provides some useful new insight, they’re about five years late to the game. The precedent was set in a much more relevant clinical report from June 2015. Since then, report after report has described these interactions, in scientific journals and more accessible reporting (we hope). Replication is essential in research - there is no need for exaggeration.

Short description: 
Adrian Devitt-Lee, Project CBD's chief science writer, is employed as a research chemist by the University College of London.